Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Asia Medical and Agricultural Laboratory and Research Center PCL Debt-to-EBITDA Related Terms
Asia Medical and Agricultural Laboratory and Research Center PCL Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asia Medical and Agricultural Laboratory and Research Center PCL Debt-to-EBITDA Chart
Asia Medical and Agricultural Laboratory and Research Center PCL Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asia Medical and Agricultural Laboratory and Research Center PCL Debt-to-EBITDA vs Hardware Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) has a Debt-to-EBITDA of 0.14 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Asia Medical and Agricultural Laboratory and Research Center PCL. This is 91% below median its historical median of 1.49. Over the past decade, Asia Medical and Agricultural Laboratory and Research Center PCL's Debt-to-EBITDA has ranged from 0.09 to 3.30. According to the industry distribution chart, Asia Medical and Agricultural Laboratory and Research Center PCL ranks #154 out of 1788 companies in the Hardware industry, placing it in the top 8.6%.
Is Asia Medical and Agricultural Laboratory and Research Center PCL's Debt-to-EBITDA too high?
Asia Medical and Agricultural Laboratory and Research Center PCL's current Debt-to-EBITDA of 0.14 is 91% below median its 10-year median of 1.49. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 3.30. The Hardware industry median Debt-to-EBITDA is 1.71. Asia Medical and Agricultural Laboratory and Research Center PCL's value of 0.14 is 91.8% below this industry median. Based on the distribution chart, Asia Medical and Agricultural Laboratory and Research Center PCL ranks #154 out of 1788 companies in the Hardware industry, which is in the top quartile — a strong position relative to peers. Overall, Asia Medical and Agricultural Laboratory and Research Center PCL has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asia Medical and Agricultural Laboratory and Research Center PCL's Debt-to-EBITDA compare to COHR and KEYS?
According to the Hardware industry distribution chart, Asia Medical and Agricultural Laboratory and Research Center PCL ranks #154 out of 1788 companies for Debt-to-EBITDA. This places Asia Medical and Agricultural Laboratory and Research Center PCL in the top 9% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.71. Asia Medical and Agricultural Laboratory and Research Center PCL's value of 0.14 is 91.8% below this benchmark. Historically, Asia Medical and Agricultural Laboratory and Research Center PCL's own Debt-to-EBITDA has ranged from 0.09 to 3.30 over the past decade. While the company's 10-year median is 1.49 vs. the industry median of 1.71, Asia Medical and Agricultural Laboratory and Research Center PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Hardware company?
The median Debt-to-EBITDA among Hardware companies is 1.71, based on 1,788 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asia Medical and Agricultural Laboratory and Research Center PCL's current Debt-to-EBITDA of 0.14 is 91.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Asia Medical and Agricultural Laboratory and Research Center PCL. For the Hardware industry, the median Debt-to-EBITDA is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asia Medical and Agricultural Laboratory and Research Center PCL's current Debt-to-EBITDA is 0.14, which is 91% below median its own 10-year median of 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asia Medical and Agricultural Laboratory and Research Center PCL stock overvalued right now?
Based on GuruFocus' analysis, Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) is currently considered Modestly Overvalued. The stock's GF Value™ is ฿2.61, compared to a current price of ฿2.92 — trading 11.9% above its estimated fair value. The current Debt-to-EBITDA is 0.14, which is 91% below median its 10-year median of 1.49 and 91.8% below the Hardware industry median of 1.71. Asia Medical and Agricultural Laboratory and Research Center PCL's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC), the current Debt-to-EBITDA is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) Overvalued in 2026?
Based on GuruFocus' analysis, Asia Medical and Agricultural Laboratory and Research Center PCL stock appears to be overvalued.
The current stock price of ฿2.92 is trading 11.9% above its estimated GF Value™ of ฿2.61.
GuruFocus considers Asia Medical and Agricultural Laboratory and Research Center PCL to be Modestly Overvalued.
Key valuation signals for BKK:AMARC:
Debt-to-EBITDA: 0.14 (91% below median its 10-year median of 1.49)
GF Value™: ฿2.61 vs. price of ฿2.92 (11.9% above fair value)
Industry Position: 91.8% below the Hardware median (#154 of 1788)
No single metric tells the full story. See the BKK:AMARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asia Medical and Agricultural Laboratory and Research Center PCL is engaged in providing comprehensive scientific services for the agriculture, food, pharmaceutical and environment sectors including testing, calibration, inspection and certification according to international quality standards. The company geographically operates only in Thailand.
91GF Score
Get the complete analysis for BKK:AMARC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:AMARC has been successfully added to your 
